Zuanic & Associates Initiates Coverage On MariMed with Overweight Rating - Report released on 2nd November 2023
Portfolio Pulse from Benzinga Newsdesk
Zuanic & Associates has initiated coverage on MariMed (OTC:MRMD) with an Overweight rating.
November 07, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MariMed's stock may see positive movement due to the Overweight rating from Zuanic & Associates.
Analyst ratings often influence the stock price. An Overweight rating suggests that the analyst believes the company's stock price will outperform the market in the future. Therefore, this news is likely to have a positive impact on MariMed's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100